Scibase Q2 - Advancing on the right track

Redeye returns with a more in-depth take on Q2 earnings. The report came in a tad lower than our expectations, but the company is on the right trajectory, with potential initial reimbursement around the corner. We somewhat revise our estimates for 2025e and update our stance on financing assumptions, leading to a slightly lowered valuation range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/